Mitochondria as a promising target for developing novel agents for treating Alzheimer's disease.

Medicinal Research Reviews
Elena F ShevtsovaSergey O Bachurin

Abstract

The mitochondria-targeting drugs can be conventionally divided into the following groups: those compensating for the energy deficit involved in neurodegeneration, including stimulants of mitochondrial bioenergetics and activators of mitochondrial biogenesis; and neuroprotectors, that are compounds increasing the resistance of mitochondria to opening of mitochondrial permeability transition (MPT) pores. Although compensating for the energy deficit and inhibition of MPT are obvious targets for drugs used in the very early stages of Alzheimer-like pathology, but their use as the monotherapy for patients with severe symptoms is unlikely to be sufficiently effective. It would be optimal to combine targets that would provide the cognitive-stimulating, the neuroprotective effects and the ability to affect specific disease-forming mechanisms. In the design of such drugs, assessment of their potential mitochondrial-targeted effects is of particular importance. The possibility of targeted drug design for simultaneous action on mitochondrial and neurotransmitter's receptors targets is, in particularly, based on the known interplay of various cellular pathways and the presence of common structural components. Of particular interest is dire...Continue Reading

References

Jul 1, 1979·Archives of Biochemistry and Biophysics·R A Haworth, D R Hunter
Jul 1, 1979·Archives of Biochemistry and Biophysics·D R Hunter, R A Haworth
May 1, 1997·Photochemistry and Photobiology·F Saitow, Y Nakaoka
Sep 23, 1997·British Journal of Pharmacology·M PfaffendorfP A van Zwieten
Nov 24, 1999·Biochemical and Biophysical Research Communications·F BonoJ M Herbert
Feb 9, 2000·Journal of Bioenergetics and Biomembranes·E Fontaine, P Bernardi
Apr 27, 2001·FEBS Letters·A J KowaltowskiA E Vercesi
Jul 21, 2001·Annals of the New York Academy of Sciences·S BachurinN Zefirov
Jul 21, 2001·Annals of the New York Academy of Sciences·S BachurinN Zefirov
Mar 22, 2002·The Journal of Biological Chemistry·Edwin J WeeberWilliam J Craigen
Oct 26, 2002·Science·Dennis J Selkoe
Mar 23, 2004·FASEB Journal : Official Publication of the Federation of American Societies for Experimental Biology·Shaida A AndrabiThomas F W Horn
Apr 8, 2004·Proceedings of the National Academy of Sciences of the United States of America·Jeffrey R GingrichMichael W Salter
Sep 29, 2004·Neuron·Robert C Malenka, Mark F Bear
Oct 1, 2004·The Biochemical Journal·Ran ZalkVarda Shoshan-Barmatz
Oct 21, 2004·Neurological Research·Xu Lin, Zhang Jun-Tian
Apr 1, 2005·The American Journal of Psychiatry·Mamoru HashimotoEtsuro Mori
Jun 22, 2005·Neuroscience Letters·Heather Y McDonald, J Martin Wojtowicz
Jul 4, 2006·Physiological Reviews·Philip G Haydon, Giorgio Carmignoto
Nov 10, 2006·American Journal of Physiology. Cell Physiology·Oliver Kann, Richard Kovács
Mar 16, 2007·Journal of Alzheimer's Disease : JAD·Jay C StrumAllen Roses
Apr 6, 2007·Journal of Pharmacological Sciences·Yuko TakayasuToshio Matsuda
May 15, 2007·The Journal of Pharmacology and Experimental Therapeutics·Thierry BordetRebecca M Pruss
Jun 28, 2007·Biochemistry·Mihaela NeculaCharles G Glabe
Aug 1, 1995·Molecular Medicine Today·J N DavisJ C Chisholm
Oct 12, 2007·FASEB Journal : Official Publication of the Federation of American Societies for Experimental Biology·Hani AtamnaBruce N Ames
Nov 8, 2007·Proceedings of the National Academy of Sciences of the United States of America·Andrey Y AbramovEvgeny Pavlov
Mar 7, 2008·Journal of Inorganic Biochemistry·E R MilaevaN S Zefirov
Mar 26, 2008·Anesthesiology·Laszlo VutskitsDenis R Morel
Dec 27, 2008·Biochemical and Biophysical Research Communications·Luis EscribanoDiana Frechilla
Mar 11, 2009·Archives of Neurology·Weiping QinGiulio M Pasinetti
May 27, 2009·Current Opinion in Chemical Biology·Maria L BolognesiCarlo Melchiorre

❮ Previous
Next ❯

Related Concepts

Related Feeds

Alzheimer's Disease: Amyloid Beta

Alzheimer's disease is a neurodegenerative disease associated with the accumulation of amyloid plaques in the brain; these plaques are comprised of amyloid beta deposits. Here is the latest research in this field.